Background-Statins improve clinical outcome of patients with atherosclerosis, but their perioperative role in patients undergoing coronary artery bypass grafting (CABG) is unclear. We hypothesized that short-term treatment with atorvastatin before CABG would improve the redox state in saphenous vein grafts (SVGs), independently of low-density lipoprotein cholesterol (LDL)-lowering. Methods and Results-In a randomized, double-blind controlled trial, 42 statin-naïve patients undergoing elective CABG received atorvastatin 40 mg/d or placebo for 3 days before surgery. Circulating inflammatory markers and malondialdehyde (MDA) were measured before and after treatment. SVG segments were used to determine vascular superoxide (O 2 ⅐Ϫ ) and Rac1 activation. For ex vivo studies, SVG segments from 24 patients were incubated for 6 hours with atorvastatin 0, 5, or 50 mol/L. Oral atorvastatin reduced vascular basal and NADPH-stimulated O 2 ⅐Ϫ in SVGs (PϽ0.05 for all versus placebo) and reduced plasma MDA (PϽ0.05), independently of LDL-lowering and of changes in inflammatory markers. In SVGs exposed to atorvastatin ex vivo, without exposure to LDL, basal and NADPH-stimulated O 2 ⅐Ϫ were significantly reduced (PϽ0.01 for both concentrations versus 0 mol/L) in association with a striking reduction in Rac1 activation and 1 membrane-bound Rac1 and p67 phox subunit. The antioxidant effects of atorvastatin were reversed by mevalonate, implying a dependence on vascular HMG-CoA reductase inhibition.
lar risk. 1 Initiation of statin therapy is recommended in patients with coronary artery disease (CAD) when low-density lipoprotein cholesterol (LDL) levels are Ͼ100 mg/dL, whereas reduction of LDL to Ͻ70 mg/dL is now considered reasonable. 1 Despite the clear benefit of statin treatment on clinical outcome of CAD patients with elevated LDL, it is still unclear whether preoperative treatment with statins is beneficial in patients with low LDL undergoing coronary artery bypass grafting (CABG) surgery. Initial observations suggested that preoperative statin treatment reduces postoperative mortality 2 and minimizes complications, 3 but these findings have not been consistently reproduced. 4 Recent evidence suggests that statin treatment after CABG inhibits saphenous vein (SV) graft disease, 5 suggesting that optimal preoperative statin treatment might be an important factor in determining the long term benefit of CABG. Thus, understanding the acute effects of preoperative statins on vein graft biology remains an important goal.
Statins have a number of pleiotropic actions, which include antiinflammatory and systemic antioxidant effects. 6 Indeed, recent evidence suggested that atorvastatin treatment exerts a systemic antioxidant effect within the first 3 days of treatment initiation in patients with atherosclerosis. 7 Experimental studies have demonstrated that statins also reduce vascular superoxide (O 2 ⅐Ϫ ) generation in animal 8 and cell culture 9 models, but the exact mechanisms are still under investigation. Statin treatment improves endothelial function in mammary artery grafts, 10 but the mechanistic effects of statins on vascular redox state in human bypass grafts, beyond those exerted through systemic changes in LDL and inflammation, remain uncertain.
We hypothesized that short-term preoperative treatment with atorvastatin may improve vascular redox state in SV grafts used in CABG, by acting directly on the vascular wall, independently of LDL-lowering or changes in systemic inflammation. We examined, for the first time in humans, the direct effect of atorvastatin on redox state in SV grafts and explored the mechanisms by which atorvastatin may regulate vascular O 2 ⅐Ϫ generation.
Methods

Study Population and Clinical Protocol
In the first part of the study, we examined whether short-term preoperative treatment with atorvastatin affects redox state in SV Diuretics, n 8 10 NS 2 n indicates no. of patients; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. There was no significant difference in serum lipid changes between atorvastatin-or placebo-treated groups (as tested by ANOVA for repeated measures with timeϫtreatment interaction). NS indicates no significant difference between the 2 treatment groups; *PϽ0.05 vs baseline. Continuous variables are expressed as meansϮSEM.
grafts used for CABG. A total of 332 patients undergoing elective CABG were screened to identify patients who were not currently taking statins, and 42 of these patients fulfilled the inclusion criteria and agreed to participate. Patients were then randomized to receive either atorvastatin 40 mg/d or placebo for 3 days preoperatively in a double-blind fashion.
Blood samples were obtained at baseline and on the morning before the operation to measure markers of systemic oxidative stress and low-grade inflammation. At the time of surgery, segments of SV grafts were obtained and transferred to the laboratory, as described previously (online-only Data Supplement). 11 Exclusion criteria were any inflammatory, infective, liver, or renal disease, malignancy, or known intolerance to statins. Patients receiving nonsteroidal antiinflammatory drugs, dietary supplements, or antioxidant vitamins or who had received any statin treatment during the last 3 months were also excluded.
In the second part of the study, we examined whether the effect of atorvastatin on vascular redox of SV grafts was independent of LDL-lowering and explored possible alternative mechanisms. To achieve that, we used an ex vivo system of human vessels, in which we exposed SV grafts directly to atorvastatin in an LDL-free environment. For these experiments, 24 additional patients with coronary artery disease undergoing elective CABG were recruited. Blood samples from these patients were obtained at the morning before CABG and samples of SV grafts were harvested and transferred to the laboratory for the ex vivo experiments. 11 Demographic characteristics of the patients are presented in the Table. The study protocol was approved by the local research ethics committee, and each patient gave written informed consent.
Determination of Vascular Superoxide Production
Vascular O 2 ⅐Ϫ production was measured in fresh segments of intact SV by using lucigenin-enhanced (5 mol/L) chemiluminescence (online-only Data Supplement). 11 These measurements are closely correlated with measurements in vascular homogenates from the same vessels, as we have demonstrated previously. 12
Ex Vivo Protocol
To examine the direct effect of atorvastatin on vascular O 2 ⅐Ϫ generation in SV grafts, SV segments obtained from 24 patients were incubated ex vivo for 6 hours, in an organ bath system containing oxygenated (95% O 2 /5% CO 2 ) Krebs-Henseleit buffer at 37°C, as we have described previously. 11 Three rings from the same SV segment were incubated with 0, 5, or 50 mol/L atorvastatin (nϭ24) for 6 hours. Both resting and NADPH-stimulated vascular O 2 ⅐Ϫ were estimated in all 3 rings from each patient at the end of the incubation period. To examine whether the effects of atorvastatin on SV grafts were mediated through direct inhibition of hydroxy-methylglutarylcoenzyme A (HMG-CoA) reductase in the vascular wall, we incubated segments of SV grafts from the same patients with 0, 5, and 50 mol/L atorvastatin in the presence and absence of mevalonate 200 mol/L for 6 hours and measured resting and NADPHstimulated vascular O 2 ⅐Ϫ by lucigenin chemiluminescence at the end of the incubation period.
Blood Sampling and Biochemical Measurements
Venous blood samples were taken after a 12-hour fast at baseline and at the morning before the operation. After centrifugation at 2000g at 4°C for 15 minutes, plasma or serum was collected and stored at Ϫ80°C until assayed.
Measurements of Plasma Malonyldialdehyde Levels
Systemic lipid peroxidation was quantified by measuring plasma malonyldialdehyde (MDA) levels (online-only Data Supplement).
Measurement of Systemic Inflammatory Markers
Plasma high-sensitivity C-reactive protein (hsCRP) was measured by particle-enhanced immunonephelometry (N Latex, Dade-Behring, Marburg, Germany). Serum interleukin (IL)-6 and soluble vascular cell adhesion molecule (sVCAM)-1 were determined by ELISA (R&D Systems, Wiesbaden-Nordenstadt, Germany).
Measurements of Serum Lipid Levels
Serum total cholesterol, LDL, high-density lipoprotein cholesterol (HDL), and triglycerides were measured by using a chromatographic enzymatic method in a Technicon automatic analyzer RA-1000 (Dade Behring).
Measurement of Vascular Rac1 Activation
Rac1 activation was evaluated by an affinity precipitation assay using the PAK1-PBD-conjugated glutathione agarose beads according to the instructions of the manufacturer (Millipore, Temecula, Calif) (online-only Data Supplement). Rac1 activation was defined by the ratio GTP-Rac1/total Rac1, as appropriate.
Immunoblotting
Immunoblotting was used to evaluate the Nox1, Nox2, and Nox4 protein level in vascular homogenates (online-only Data Supplement). The p47 phox , p67 phox , and Rac1 content in the membrane 
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subfraction was compared in the presence or absence of atorvastatin treatment (ex vivo) (online-only Data Supplement).
Oxidative Fluorescent Microtopography
In situ superoxide production was determined in vessel cryosections with fluorescent dye dihydroethidium staining (online-only Data Supplement).
Statistical Analysis
All continuous variables were tested for normal distribution by using Kolmogorov-Smirnov test. Nonnormally distributed variables were log-transformed for analysis and are presented in a nonlogarithmic format as median[25th to 75th percentile]. Normally distributed variables are presented as meansϮSEM. Power calculations based on our previous studies 11 suggested that 20 subjects per group would be able to detect a 30% difference in vascular O 2 ⅐Ϫ generation with ␣ϭ0.05 and power 90%.
Continuous variables between 2 independent groups were compared by using unpaired t test, whereas categorical variables were compared by using 2 test, as appropriate. The effect of treatment on plasma biomarkers was compared between the 2 groups by using 2-way ANOVA for repeated measures with timeϫtreatment interaction. In the ex vivo experiments (where vascular segments from the same vessel were incubated with increasing concentrations of atorvastatin), we performed an overall repeated measures ANOVA, followed by Bonferroni post hoc correction for individual comparisons between groups. Correlations between continuous variables were assessed by using bivariate analysis, and Pearson's coefficient was estimated. All statistical tests were performed by using SPSS v17.0, and PϽ0.05 was considered statistically significant.
Results
Effects of Short-Term Oral Atorvastatin Treatment Before CABG
There was no significant difference in demographic characteristics or baseline lipid levels between the study groups in the clinical trial (Table) .
We first examined the effects of preoperative treatment with atorvastatin 40 mg/d for 3 days on vascular O 2 ⅐Ϫ generation in SV grafts used for CABG. Atorvastatin significantly reduced basal and NADPH-stimulated vascular O 2 ⅐Ϫ (Figure 1 ) and Rac1 activation in SV grafts (Figure 1 ), suggesting that O 2 ⅐Ϫ generation in SV grafts occurred by suppressing Rac1-mediated NADPH-oxidase stimulation. Under basal conditions, nitric oxide synthase (NOS) inhibition caused a reduction of vascular O 2 ⅐Ϫ , suggesting that NOS was largely uncoupled in these vessels. As shown in Figure 1 , atorvastatin reversed N G -nitro-Larginine methyl ester (L-NAME)-inhibitable O 2 ⅐Ϫ generation, suggesting an improvement of NOS coupling in these SV grafts (Figure 1 ). However, short-term atorvastatin treatment had no impact on Nox1, Nox2, or Nox4 protein levels in these grafts ( Figure 2 ). These findings were in line with the significant reduction of plasma MDA levels observed in the treated compared to placebo patients (Figure 3) , indicating an effect on systemic oxidative stress.
Importantly, the borderline reduction in serum LDL in the atorvastatin-treated group was not significantly different from that observed in the placebo-treated group (by ANOVA with timeϫtreatment interaction). In addition, there was no significant association between circulating LDL and superoxide production; 574 ), suggesting that mechanisms other than LDL-lowering are responsible for the observed rapid reduction in systemic and vascular oxidative stress. Because systemic inflammation has a direct impact on vascular and systemic oxidative stress, 13 and chronic statin treatment has been shown to have antiinflammatory properties, 1 we examined whether atorvastatin exerts its effects on O 2 ⅐Ϫ generation in SV grafts by decreasing systemic low-grade inflammation. We found that atorvastatin had no impact on circulating IL-6, sVCAM-1, or hsCRP, indicating that 3 days of statin therapy is insufficient to induce a detectable effect on systemic inflammation (Figure 3 
Effects of Atorvastatin on Saphenous Vein Graft Redox State Ex Vivo
To further examine whether atorvastatin exerts its effects on O 2 ⅐Ϫ generation in SV grafts directly, independently of LDL-lowering, we used an ex vivo system, in which SV graft segments (nϭ24) were incubated with atorvastatin 0, 5, or 50 mol/L for 6 hours. We observed that both concentrations of atorvastatin induced a significant reduction of resting and NADPH-stimulated O 2 ⅐Ϫ generation in SV grafts (Figure 4 ). This effect was independent of resting or NADPH-stimulated O 2 ⅐Ϫ at baseline. The effect on intact vessels was confirmed in homogenates of SV grafts (nϭ7), where O 2 ⅐Ϫ generation was reduced from 4. (Figure 4 ), suggesting that the rapid inhibition of NADPH-oxidase by atorvastatin may be mediated by an effect on Rac1. Moreover, atorvastatin significantly reduced the membrane-bound NADPH-oxidase subunit p67 phox , as well as Rac1 ( Figure 5 ). We next examined whether atorvastatin exerts its effects on O 2 ⅐Ϫ generation in SV grafts through the inhibition of the HMG-CoA pathway. By inhibiting HMG-CoA reductase, atorvastatin prevents the synthesis of mevalonate; therefore, mevalonate administration should restore the atorvastatininduced biological changes through this pathway. Accordingly, serial segments of the same SV grafts were incubated with atorvastatin 0, 5, or 50 mol/L for 6 hours in the presence or absence of mevalonate (200 mol/L). We observed that the effect of atorvastatin on resting and NADPHstimulated O 2 ⅐Ϫ was reversed by mevalonate ( Figure 6 ), suggesting that inhibition of HMG-CoA reductase within the vascular wall is the main mechanism by which atorvastatin exerts these rapid effects on O 2 ⅐Ϫ generation in SV grafts. To examine whether atorvastatin also exerts a direct effect on endothelial (e)NOS coupling in SV grafts, we estimated the changes in the L-NAME-inhibitable O 2 ⅐Ϫ fraction in these vessels. We observed that ex vivo incubation of SV grafts with atorvastatin 5 or 50 mol/L for 6 hours reversed eNOS uncoupling, an effect that was prevented by coincubation with mevalonate ( Figure 6 ). This finding suggests that atorvastatin contributes to the overall reduction of vascular O 2 ⅐Ϫ generation by directly improving eNOS-coupling in these grafts.
To further examine which vascular components are responsible for these effects, we performed dihydroethidium staining in vascular cryosections from the ex vivo study. We observed that atorvastatin rapidly reduced O 2 ⅐Ϫ generation in both the vascular wall (from 30Ϯ12 U/mm 2 in 0 mol/L to 16Ϯ0.8 U/mm 2 in 5 mol/L and 14Ϯ0.7 U/mm 2 in 50 mol/L with PϽ0.01 for both versus 0 mol/L) and vascular endothelium (from 0.4Ϯ0.014 U/mm in 0 mol/L to 0.02Ϯ0.006 U/mm in 5 mol/L and 0.02Ϯ0.005 U/mm in 50 mol/L, PϽ0.01 for both versus 0 mol/L) (Figure 7) .
Discussion
In the present study, we demonstrate that preoperative treatment with atorvastatin 40 mg/d for 3 days reduces O 2 ⅐Ϫ generation in SV grafts used for CABG surgery. We also demonstrate that atorvastatin exerts its effects by directly inhibiting HMG-CoA reductase in the vascular wall, independently of LDL-lowering and systemic inflammation. Atorvastatin suppresses Rac1-mediated activation of vascular NADPH-oxidase, although it also reduces membrane-bound P67 phox subunit of the enzyme. We also demonstrate that atorvastatin directly improves eNOS-coupling in these grafts, suggesting an additional mechanism by which statins exert their vascular antioxidant effects. These novel findings indicate that even short-term statin treatment during the preoperative period may have an important beneficial effect on SV graft biology and redox state.
Recent evidence suggests that statins reduce cardiovascular risk even in low-risk subjects with LDL concentrations of Ͻ130 mg/dL, especially in the presence of high background inflammatory status. 1 In addition, evidence suggests that preoperative statin treatment reduces mortality post CABG 2 and minimizes postoperative complications, 3 although a recent retrospective study 5 suggested that statins may also improve long-term SV grafts patency, a finding that requires further investigation. It is, therefore, important to understand how preoperative treatment with statins affects the biology of SV grafts, including those patients with relatively low LDL.
Vascular O 2 ⅐Ϫ is a critical feature regulating vascular homeostasis, whereas NADPH-oxidase, a major source of O 2 ⅐Ϫ in the vascular wall, 14 could potentially be a therapeutic target in atherosclerosis. 15 Evidence suggests that short-term treatment with atorvastatin modifies systemic oxidative stress, 7 but the mechanisms mediating this effect in humans are unclear. Experimental studies have demonstrated that statins reduce endothelium-derived O 2 ⅐Ϫ in an animal model 8 and inhibit intimal hyperplasia in rabbit vein grafts. 16 These effects had been suggested to be partly attributable to improvement of eNOS activity 17 or suppression of Rac1mediated activation of NADPH-oxidase in these models, 8 but the relevance of these observations to the acute vascular effects of statins in humans have remained unclear. In the present study, we now demonstrate that short-term treatment with atorvastatin 40 mg/d for 3 days before CABG suppresses O 2 ⅐Ϫ generation in SV grafts in statin-naïve patients. We also demonstrate that this effect is attributable to a decrease of NADPH-oxidase activity in the vascular wall. Although short-term atorvastatin treatment had no effect of the expression of Nox1, Nox2, or Nox4 complexes of NADPH-oxidase in these grafts, we demonstrate that it decreases the activation of Rac1, a GTPase with a known regulatory role in NADPHoxidase activation. 14 Atorvastatin also reduced plasma MDA, indicating a reduction of systemic oxidative stress, an effect that was independent of LDL changes.
Systemic inflammation is a stimuli for O 2 ⅐Ϫ generation in the vascular wall, 13 whereas statins exert a global antiinflammatory effect. 1 It is, therefore, possible that atorvastatin exerts its antioxidant effects on O 2 ⅐Ϫ generation in SV grafts by modulating systemic low-grade inflammation. However, in the present study, circulating IL-6, hsCRP, and sVCAM-1 remained unchanged after treatment with atorvastatin for 3 days and were unrelated to vascular O 2 ⅐Ϫ . These findings are consistent with previous reports indicating that short-term treatment (Ͻ5 days) with atorvastatin does not affect systemic low-grade inflammation, 18 confirming that systemic inflammation did not mediate the effect of atorvastatin on SV graft redox state in the present study.
To further examine whether the effect of atorvastatin on vascular redox was independent of LDL-lowering or systemic low-grade inflammation, we used an ex vivo model of human SV grafts, and we demonstrated that atorvastatin, by acting directly on the vascular wall, suppresses Rac1 activation and reduces membrane-bound Rac1 and p67 phox subunit, resulting into a reduction of resting and NADPH-stimulated O 2 ⅐Ϫ in SV grafts. This effect was reversed by mevalonate, suggesting that inhibition of HMG-CoA reductase is the main mechanism by which atorvastatin exerts its effects on vascular redox state.
Furthermore, NADPH-oxidase, the uncoupled eNOS, is another major source of O 2 ⅐Ϫ in the vascular wall 19 ; therefore, recoupling of eNOS may be a rational therapeutic goal in SV grafts biology. In endothelial cell culture models, statins improve eNOS-coupling and reduce cellular O 2 ⅐Ϫ generation, 20 but their effect on eNOS-coupling in human SV grafts is unknown. In the present study, we demonstrate that even short-term oral treatment with atorvastatin improves eNOScoupling in human SV grafts. Moreover, we demonstrate that atorvastatin improves eNOS-coupling in these vessels by directly inhibiting HMG-CoA reductase in the vascular wall, in an ex vivo system of human SV grafts.
The results of the present study may also be extrapolated to other vascular beds. Indeed, although our study examined the impact of short-term statin treatment on the mechanisms regulating redox state in SV grafts of patients undergoing CABG, our results may also be applicable to arterial vascular beds. Shortterm treatment with atorvastatin rapidly improves endothelial function in the brachial artery even within 24 hours, 21 by mechanisms independent of lipid-lowering. 6 This may also be mediated by an effect on Rac1 activation, modification of NADPH-oxidase activity, and improvement of eNOS-coupling, providing a possible explanation for the clinical benefits observed after short-term statin treatment of patients with acute coronary events. 22 However, further studies focused on human arterial tissue are required to investigate this hypothesis.
In conclusion, we demonstrate, for the first time in humans, that preoperative treatment of statin-naïve patients with atorvastatin 40 mg/d for 3 days inhibits HMG-CoA reductase directly in the vascular wall, independently of LDL-lowering or systemic low-grade inflammation. This results into a reduction of O 2 ⅐Ϫ generation in SV grafts by modifying Rac1-mediated activation of NADPH oxidase, as well as by modifying eNOS-coupling. These novel findings may have major clinical implications, because they support the notion that even in patients with relatively low LDL, preoperative treatment with statins has direct beneficial effects on the biology of SV grafts used in CABG and may have an impact on the patency of these grafts.
